Laurence Albigès, MD, PhD, on the Benefit of Nivolumab Plus Ipilimumab for Advanced RCC

Laurence Albigès, MD, PhD, speaks to how patients with treatment-naïve advanced or metastatic renal cell carcinoma can benefit from treatment with nivolumab and ipilimumab.

During the 2022 Genitourinary Cancers Symposium, Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, spoke with CancerNetwork® about the benefit of treatment with nivolumab (Opdivo)/ipilimumab (Yervoy) in patients with treatment-naïve advanced or metastatic renal cell carcinoma based on findings from the CheckMate 214 study (NCT02231749).

Albigès highlighted the promising and potentially sustained responses that occurred with the combination plus the positive quality of life and safety profile patients experienced following treatment.

Transcript:

The key takeaway beyond the overall survival benefit is about the likelihood of achieving a 10% to 12% complete response [rate] in our patients. It is also about sustained benefit over time, as I mentioned with longer follow up. And we do know that for some of these patients, treatment discontinued [but they] maintained a great response. It’s really the long-term benefit that is a key message. In terms of safety, our colleagues are familiar with the fact that we need to closely monitor patients, especially in the first 6 months when we’re [administering] the doublet part of this regimen—nivolumab plus ipilimumab. This is where immune-related toxicity may occur. Ultimately, I want to comment on the quality of life that has been reported with this regimen. In these patients, despite the risk of immune-mediated toxicity, we did see a great increase in terms of quality of life for our patients.

Reference

Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352